Multiple curative gene therapies for hemophilia are getting closer to the market, but in the days of restricted affordability how do we ensure that these life-changing therapies will be able to get in the hands of the patient that need them most?

Precision gathered a panel of experts to discuss this issue in its recent webinar Gene Therapies in Hemophilia.

Ironically, on the morning of the discussion, the US Food and Drug Administration issued a Complete Response Letter to BioMarin citing durability concerns for its hemophilia gene therapy and the need to generate additional data—something the panel debated in a more general context.

Download a summary white paper with key takeaways from the webinar here!